No data to show
OTCM
GMVDF
Market cap2kUSD
Mar 21, Last price
0.00USD
Name
G Medical Innovations Holdings Ltd
Chart & Performance
P/E
—
P/S
0.00
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
269.07%
Revenues
4m
-12.61%
Net income
-14m
L-6.25%
CFO
-18m
L+60.77%
Profile
G Medical Innovations Holdings Ltd, together with its subsidiaries, an early commercial stage healthcare company, engages in the development of next generation mobile health and telemedicine solutions in the United States, China, and Israel. The company's products include Prizma, a plug-and-play medical device that measures vital signs with electronic medical records functionality and clinical grade reporting standards; and Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiogram data continuously for up to 14 days. It also develops Wireless Vital Signs Monitoring System, a solution that provides continuous real time monitoring of vital signs and biometrics. In addition, it offers monitoring services, including independent diagnostic testing facility monitoring and private monitoring services. The company was incorporated in 2014 and is based in Rehovot, Israel.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑09 | |
| Income | |||||||
Revenues | 4,420 -12.61% | ||||||
Cost of revenue | 30,784 | ||||||
Unusual Expense (Income) | |||||||
NOPBT | (26,364) | ||||||
NOPBT Margin | |||||||
Operating Taxes | 16 | ||||||
Tax Rate | |||||||
NOPAT | (26,380) | ||||||
Net income | (13,958) -6.25% | ||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 3,321 | ||||||
BB yield | |||||||
| Debt | |||||||
Debt current | 1,809 | ||||||
Long-term debt | 676 | ||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | 2,190 | ||||||
| Cash flow | |||||||
Cash from operating activities | (18,479) | ||||||
CAPEX | (2,121) | ||||||
Cash from investing activities | (2,123) | ||||||
Cash from financing activities | 14,863 | ||||||
FCF | (21,963) | ||||||
| Balance | |||||||
Cash | 295 | ||||||
Long term investments | |||||||
Excess cash | 74 | ||||||
Stockholders' equity | (106,144) | ||||||
Invested Capital | 103,665 | ||||||
ROIC | |||||||
ROCE | 1,063.49% | ||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | 3.28 96.41% | ||||||
Market cap | |||||||
EV | |||||||
EBITDA | (25,152) | ||||||
EV/EBITDA | |||||||
Interest | 14,350 | ||||||
Interest/NOPBT | |||||||